目次

Table of Content

1. Research Methodology

2. What is Photodynamic Cancer Therapy?
2.1 Overview
2.2 Advantage of Photodynamic Cancer Therapy
2.3 Evolution of the Photodynamic Cancer Therapy

3. Clinical Need For Photodynamic Therapy In Oncology

4. Procedural Framework For Photodynamic Cancer Therapy
4.1 Procedure for Photodynamic Therapy
4.2 Administering Photosensitizers To Body
4.3 Oxygen: A Vital Substrate in Photodynamic Therapy
4.4 Light Source: Key to Safe and Effective Photosensitizer Activation

5. Optimizing Photosensitizer Delivery For Photodynamic Therapy
5.1 Organic Nanoparticles: Enhancing Drug Loading Capacity and Solubility
5.2 Inorganic Nanocarriers As Vehicles For Photosensitizers In Photodynamic
Therapy

6. Anti-Tumor Activity Of Photodynamic Therapy
6.1 Direct Tumor Damage By Photodynamic Therapy
6.2 Vascular Damage
6.3 Inflammatory and Immune Response

7. Multiple Cancer Treatments Using Photodynamic Therapy
7.1 Skin Cancer
7.2 Prostate Cancer
7.3 Oral Lesions and Esophageal Cancer
7.4 Lung Cancer
7.5 Breast Cancer
7.6 Brain Tumors
7.7 Head and Neck Cancer
7.8 Gynecological Cancers
7.9 Colorectal Cancer
7.10 Biliary and Pancreatic Cancers

8. Global Cancer Photodynamic Therapy Market Outlook
8.1 Current Market Scenario
8.2 Future Market Opportunity

9. Photodynamic Therapy Market Analysis By Region
9.1 North America
9.2 Europe
9.3 Asia Pacific
9.4 Latin America, Middle East and Africa

10. Global Cancer Photosensitizers Clinical Pipeline Overview
10.1 By Phase
10.2 By Country
10.3 By Company
10.4 By Indication

11. Global Photosensitizers Clinical Pipeline By Company, Indication and Phase
11.1 Preclinical
11.2 Phase I
11.3 Phase-I/II
11.4 Phase-II
11.5 Phase-III

12. Marketed Photosensitizers By Company and Indication

13. Synergistic Photodynamic Therapy Approaches For Tumor Eradication

14. Advancements In Photodynamic Therapy Segment

15. Global Photodynamic Cancer Therapy Market Dynamics
15.1 Favorable Parameters and Opportunities
15.2 Challenges to Future Market Growth

16. Competitive Landscape
16.1 Asieris Pharmaceuticals
16.2 Aura Biosciences
16.3 Biofrontera AG
16.4 Biolitec
16.5 Coherent
16.6 Galderma
16.7 Hemerion Therapeutics
16.8 ImPact Biotech
16.9 Invion
16.10 Luzitin
16.11 Modulight Corporation
16.12 Molteni Farmaceutici
16.13 PCI Biotech
16.14 PhotoBiotics
16.15 Photolitec
16.16 photonamic
16.17 Pinnacle Biologics
16.18 Rakuten Medical
16.19 Theralase Technologies
16.20 SBI Pharmaceuticals
16.21 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
16.22 Soligenix
16.23 Sun Pharma

List of Figures & Tables
Figure 2-1: Cancer Photodynamic Therapy - Superior Targeted Noninvasive Alternative
Figure 2-2: Cancer Photodynamic Therapy - Evolution
Figure 3-1: Cancer Photodynamic Therapy - Need
Figure 4-1: Cancer Photodynamic Therapy - Working Principle
Figure 4-2: Desired Features of Ideal Photosensitizer
Figure 4-3: Photodynamic Therapy - Cellular Mechanism
Figure 4-4: Photodynamic Therapy - Common Light Sources
Figure 5-1: Photodynamic Therapy - Drug Delivery Systems
Figure 5-2: Photosensitizer Drugs - Liposome-Based Delivery
Figure 5-3: Quantum Dot - Structure
Figure 5-4: Gold Nanoparticles - Targeted Photosensitizer Delivery System
Figure 6 -1: Photodynamic Therapy - Tumor Cell Apoptosis Induction
Figure 6-2: Photodynamic Therapy - Vascular Damage Induction
Figure 7-1: CASE2621 Phase 1/2 (NCT05020912) Trial - Study Initiation and Completion Year
Figure 7-2: ALA-BCC-CT013 Phase 3 (NCT03573401) Trial - Study Initiation and Completion Year
Figure 7-3: PDT-MDS-BCC-24 Phase 1 (NCT06623201) Trial - Study Initiation and Completion Year
Figure 7-4: JointAPHSHC/2014-002746-50 Phase 1/2 (NCT02367547) Trial - Study Initiation and Completion Year
Figure 7-5: STU00211723 Phase 2 (NCT04429308) Trial - Study Initiation and Completion Year
Figure 7-6: ALA-AK-CT019 Phase 3 (NCT05662202) Trial - Study Initiation and Completion Year
Figure 7-7: PCM304 Phase 3 (NCT01875393) Trial - Study Initiation and Completion Year
Figure 7-8: PCM204 Phase 2 (NCT03315754) Trial - Study Initiation and Completion Year
Figure 7-9: SPC11-01-110 Phase 1/2 (NCT03067051) Trial - Study Initiation and Completion Year
Figure 7-10: 2024-FXY-183 Phase 4 (NCT06437288) Trial - Study Initiation and Completion Year
Figure 7-11: Padeliporfin Phase 1 (NCT03133650) Trial - Study Initiation and Completion Year
Figure 7-12: CA279862 Phase 2 (NCT06876038) Trial - Study Initiation and Completion Year
Figure 7-13: Lung Cancer - Photodynamic Therapy Procedure
Figure 7-14: I-3845023 Phase 2 (NCT06943664) Trial - Study Initiation and Completion Year
Figure 7-15: Porfimer Sodium Phase 1 (NCT04836429) Trial - Study Initiation and Completion Year
Figure 7-16: I 62118 Phase 1 (NCT03678350) Trial - Study Initiation and Completion Year
Figure 7-17: LCM101 Phase 1 (NCT05918783) Trial - Study Initiation and Completion Year
Figure 7-18: KTI-21-01 Phase 1 (NCT052374915) Trial - Study Initiation and Completion Year
Figure 7-19: F0009-01 Phase 3 (NCT06417281) Trial - Study Initiation and Completion Year
Figure 7-20: STUDY22120058 Phase 2 (NCT06907485) Trial - Study Initiation and Completion Year
Figure 7-21: UKM2013_0034 Phase 2 (NCT04738162) Trial - Study Initiation and Completion Year
Figure 7-22: WWU20_0041 Phase 1/2 (NCT05590689) Trial - Study Initiation and Completion Year
Figure 7-23: HTX-GBM-01 Phase 1/2 (NCT05736406) Trial - Study Initiation and Completion Year
Figure 7-24: GL 01 Phase 2 (NCT03897491) Trial - Study Initiation and Completion Year
Figure 7-25: PhotodiVIN Phase 2 (NCT05104099) Trial - Study Initiation and Completion Year
Figure 7-26: Gleolan Phase 1/2 (NCT06307548) Trial - Study Initiation and Completion Year
Figure 7-27: CARP Phase 4 (NCT05551299) Trial - Study Initiation and Completion Year
Figure 7-28: PNCM101 Phase 1 (NCT05919238) Trial - Study Initiation and Completion Year
Figure 7-29: MC230404 Phase 2 (NCT06381154) Trial - Study Initiation and Completion Year
Figure 8-1: Global - Cancer Photodynamic Therapy Market Opportunity (US$ Billion), 2024-2030
Figure 8-2: Global - Share of Cancer In Photodynamic Therapy (%), 2024 and 2030
Figure 8-3: Global - Cancer Photodynamic Therapy by Region (%), 2024 and 2030
Figure 8-4: US - Cancer Photodynamic Therapy Market Opportunity (US$ Billion), 2024 and 2030
Figure 8-5: Europe - Cancer Photodynamic Therapy Market Opportunity (US$ Billion), 2024 and 2030
Figure 8-6: Asia - Cancer Photodynamic Therapy Market Opportunity (US$ Billion), 2018 and 2026
Figure 8-7: Global Cancer Photodynamic Therapy - Future Opportunities
Figure 10-1: Global - Cancer Photosensitizers Clinical Pipeline By Phase (Numbers), 2025 Till 2030
Figure 10-2: Global - Cancer Photosensitizers Clinical Pipeline By Company (Numbers), 2020 till 2026
Figure 10-3: Global - Cancer Photosensitizers Clinical Pipeline By Company (Numbers), 2025 Till 2030
Figure 10-4: Global - Cancer Photosensitizers Clinical Pipeline By Indication (Numbers), 2025 Till 2030
Figure 13-1: Cancer Photodynamic Therapy - Limitations
Figure 15-1: Global Cancer Photodynamic Therapy Market - Drivers and Opportunities
Figure 15-2: Global Cancer Photodynamic Therapy Market - Challenges and Restraints
Figure 15-3 : Cancer Photodynamic Therapy - Scientific Limitations
Figure 15-4 : Cancer Photodynamic Therapy Market - Commercial Challenges
Table 13-1: Photodynamic Therapy - Combination Approaches In Clinical Trials